Men on gonadotropin-releasing hormone agonists (Lupron, etc) for prostate cancer

August 2001

Men on gonadotropin-releasing hormone agonists (Lupron, etc) for prostate cancer seem to have a higher risk of osteoporosis.

This makes sense.

These drugs slow the growth of prostate cancer by suppressing testosterone production.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

new thinking on which women should take hormone replacement therapy
Cardiology ACE inhibitors and diuretics can prevent recurrent stroke
Cardiology measuring C-reactive protein levels
Infectious Diseases flu vaccine delay again this year
Infectious Diseases Valtrex (valacyclovir) for just 3 days for treating recurrent genital herpes
Pediatrics iron deficiency might reduce cognitive ability in school-aged kids
Osteoporosis best way to switch women from estrogen replacement therapy to Evista (raloxifene)
Osteoporosis Men on gonadotropin-releasing hormone agonists (Lupron, etc) for prostate cancer
Parkinson's Disease new treatment algorithm to select drugs for Parkinson's disease
Dermatology topical phenytoin for wound healing
Dermatology Estrostep for acne in young women
Anticoagulants new guidelines on using low-molecular-weight heparins (Lovenox, Fragmin, Innohep)
Thyroid Disorders plans to phase out any levothyroxine products that don't have an approved NDA
Medicare demands for lower cost prescription drugs
Gastroenterology acid blockers for some patients with irritable bowel syndrome
Practice California Board is talking about accepting NABPLEX and licensing pharmacists from other states
Cholesterol Bayer is taking Baycol (cerivastatin) off the market